European Academy of Dermatology and Venereology Congress

Significant improvements were seen in atopic dermatitis symptoms in patients treated with an anti-OX40 monoclonal antibody, as well as continued improvement after discontinuation, according to phase 2 trial results.

Patient-reported psoriasis signs and symptoms improvement was significantly better in those treated with deucravacitinib over placebo and apremilast, according to two clinical trials presented at the EADV Congress virtual meeting.

Acne scars lead to a significant amount of emotional burden that impacts daily life, according to a poster presented at the EADV Congress virtual meeting.

Photodynamic therapy could be a beneficial second-line therapy for the treatment of hidradenitis suppurativa, according to a poster presented at the EADV Congress virtual meeting.

An extension study found atopic dermatitis patients continuously treated with tralokinumab had long-term improvement in severity and those with interrupted treatment matched improvement after 12 weeks.

Long-term treatment with tapinarof cream 1% was well tolerated and effective in continuing plaque psoriasis improvement, according to an extension study presented at the EADV Congress virtual meeting.

Facial and body repigmentation was significant in patients with vitiligo treated with ruxolitinib cream, according to two phase 3 studies presented at the EADV Congress virtual meeting.

Patient reported data from two phase 3 trials found roflumilast cream 0.3% significantly reduced itch severity and impact in psoriasis patients, according to a presentation at the EADV Congress virtual meeting.

A link between condylomas, or genital warts, and the human leukocyte antigen system could suggest a genetic risk for contraction, according to a poster presented at the EADV Congress virtual meeting.

Remibrutinib provided significant improvement in chronic spontaneous urticaria in a phase 2b dose affirming trial presented at the EADV virtual congress.